Niclosamide formulations for the treatment of influenza infections
Ended Project Grant Awarded Last action
- Award ID
- R43AI167394
- Recipient
-
Molecular Express, Inc. UEI R1JMHFESEKD5
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $596,958
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Place of performance
- CRYSTAL CITY, CA 90220, USA
Award details come from USAspending.gov.
Description
- Abstract
- The principal goal of this project is to demonstrate that the FDA-approved anthelminthic drug, niclosamide, can be reformulated in a synthetic lung surfactant which can be aerosolized for the treatment of infections caused by respiratory viruses. The studies proposed in this sbir phase I application will be focused on testing this concept by suspending niclosamide loaded liposomes in our proprietary lung surfactant technology (NICLOSURF) and testing candidate NICLOSURF formulations in a mouse influenza challenge model. The effectiveness of NICLOSURF as a treatment for respiratory viral infections caused by influenza will be evaluated.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $298,479 | |
| Original award | $298,479 |
Quick answers
Who received award R43AI167394?
R43AI167394 was awarded to Molecular Express, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 8, 2022.
How much is award R43AI167394 worth?
$596,958 has been obligated on R43AI167394.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award